Biotechlineup
Nov 13, 12:03 AM
$BCTX When an investor asked whether BriaCell's post-readout valuation would land closer to
$400 million or
$4 billion, Jameson pointed directly to the
$2.5 billion peak sales figure and said investors could "do the math on an appropriate multiple."
In biotech M&A and licensing, commercial-stage or Phase 3-validated oncology assets are typically valued at 2x to 4x peak annual sales (after factoring in risk, manufacturing costs, and time to peak)
At a conservative 1x–2x peak sales multiple: A
$2.5B peak sales drug implies a potential long-term asset value of
$2.5 billion to
$5.0 billion.
Why BriaCell trades around a 30M–
$50M market cap today: The market is applying a steep "probability of success" discount (often 90%+) due to binary Phase 3 risk, small-cap biotech financing overhang, and past share dilution. If the 144-event interim readout hits statistical significance, that discount collapses overnight which is why Jameson called it an "explosive and binary" inflection point.
0 replies
